Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Support

This activity is supported by educational grants from Amgen and Sanofi Genzyme.

Optimizing Treatment Throughout the Prostate Cancer Continuum: How the Experts Think & Treat

Release Date: March 25, 2021
Expiration Date: March 25, 2022

Activity Overview

This online, on-demand virtual symposium brings together renowned experts in prostate cancer treatment and clinical research for a deep dive into the advances made in the management of the disease. This program offers you the chance to learn about current and emerging treatment strategies, evidence-based guidelines, methods for overcoming treatment challenges, and multidisciplinary approaches to the care of patients with prostate cancer across the disease spectrum. Throughout the program, case studies will be used to provide insight into how the experts would treat patients with prostate cancer.

This educational activity is an archive of a live virtual symposium held on February 26, 2021.

Acknowledgement of Commercial Support

This activity is supported by educational grants from Amgen and Sanofi Genzyme.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational activity is directed toward medical oncologists, urologists, surgical oncologists, and radiation oncologists who treat patients with prostate cancer. Nurse practitioners, physician assistants, nurses, and other health care professionals interested in the treatment of prostate cancer are also invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Describe key data and emerging evidence from recent clinical studies for the management of patients with prostate cancer throughout the disease continuum
  • Outline emerging strategies from recent data and ongoing late-phase clinical trials investigating novel therapies for prostate cancer
  • Integrate data from recent clinical trials and evidence-based guidelines to select initial and subsequent therapies in the management of patients with prostate cancer
  • Optimize treatment for patients with early-stage and advanced prostate cancer by using recent data to create personalized treatment strategies

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities.


Celestia S. Higano, MD, FACP
Celestia S. Higano, MD, FACP
Professor, Department of Urologic Sciences
University of British Columbia
Medical Director, Prostate Cancer Supportive Care Program
Vancouver Prostate Centre
Vancouver, Canada

Disclosures: Grant Research Support: Aptevo Therapeutics, Astellas Pharma, AstraZeneca, Clovis Oncology, Dendreon, eFFECTOR Therapeutics, Emergent BioSolutions, Genentech, Hoffmann-La Roche, Pfizer; Consultant: Astellas Pharma, Bayer, Ferring, Genentech, Janssen, Menarini Group, Myovant Sciences, Tolmar; Speakers Bureau: Advantagene, AstraZeneca, Exelixis; Stockholder: Spouse holds stock in CTI BioPharma.

Julie N. Graff, MD
Julie N. Graff, MD
Associate Professor of Medicine
Oregon Health & Science University
Chief, Hematology/Oncology
VA Portland Health Care System
Portland, OR

Disclosures: Grant Research Support: Astellas/Medivation, Janssen, Merck, Sanofi Genzyme.

Todd M. Morgan, MD
Todd M. Morgan, MD
Professor, Urology
Chief, Division of Urologic Oncology
University of Michigan
Ann Arbor, MI

Disclosures: Grant Research Support: Decipher Biosciences, Myriad Genetics.

Daniel Spratt, MD
Daniel Spratt, MD
Radiation Oncology Laurie Snow Endowed Professor
Associate Chair, Clinical Research
University of Michigan
Ann Arbor, MI

Disclosures: Grant Research Support: Janssen; Consultant: Boston Scientific, Janssen.

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By